Acticor Biotech: green light for UK study
This randomized, double-blind, placebo-controlled Phase 2b study will include over 200 patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention.
The study will be conducted at two UK hospitals: Queen Elizabeth Hospital, Birmingham, and Northern General Hospital, Sheffield. Patient recruitment is scheduled to begin by the end of 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction